Experimental analysis of inhibitory effect of n-3 polyunsaturated fatty acid on cholesterol gallstone.
n-3多不饱和脂肪酸对胆固醇胆结石抑制作用的实验分析。
基本信息
- 批准号:08670553
- 负责人:
- 金额:$ 1.41万
- 依托单位:
- 依托单位国家:日本
- 项目类别:Grant-in-Aid for Scientific Research (C)
- 财政年份:1996
- 资助国家:日本
- 起止时间:1996 至 1997
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
The incidence of cholesterol (CH) gallstone in Japan has dramatically increased in the past 50 years, during which intake of fish oil or n-3 polyunsaturated fatty acids (PUFA) has sharply declined. We aimed to clarify both in vivo and in vitro our hypothesis that eicosapentaenoic acid (EPA), a n-3 PUFA,might have a preventive effect on CH gallstone. The effect of EPA was compared with other fatty acids or bezafibrate in hamsters fed CH-rich diet. It was revealed that among various fatty acids only EPA inhibits the CH crystallization and gallstone formation in the hamster. This was accompanied by both increased total concentration and altered fatty acid composition (an increased EPA and decreased linoleic acid and arachidonic acid) of biliary phospholipids. How these changes in biliary lipids relate to the preventive effects was further studied in vitro. In the model bile system, increases in phosphatidylcholine (PC) that contains either EPA (16 : 0-20 : 5 PC), linoleic acid (16 : 0-18 : 2 PC), or arachidonic acid (16 : 0-20 : 4 PC) all decreased the vesicular CH saturation and similarly exerted potent and dose-dependent inhibitory effect on CH crystallization. These effects were clearly stronger than bile acids. Finally, in a culture system of gallbladder epithelia, EPA significantly inhibited the arachidonic acid-induced mucus glycoprotein secretion. The dual inhibitory effects of EPA on the two key pathogenetic factors (CH crystallization and mucus glycoprotein secretion) suggest critical roles of the n-3 PUFA in the formation and prevention of CH gallstone disease.
在过去的50年里,日本胆固醇(CH)胆结石的发病率急剧上升,而在此期间,鱼油或n-3多不饱和脂肪酸(PUFA)的摄入量急剧下降。我们的目的是在体内和体外澄清我们的假设,即二十碳五烯酸(EPA),一种n-3 PUFA,可能对CH胆结石有预防作用。比较了EPA与其他脂肪酸或苯扎贝特对富含ch的仓鼠的影响。结果表明,在多种脂肪酸中,只有EPA能抑制仓鼠胆石的形成和CH的结晶。这伴随着胆磷脂总浓度的增加和脂肪酸组成的改变(EPA增加,亚油酸和花生四烯酸减少)。在体外进一步研究了这些胆道脂质的变化与预防作用的关系。在模型胆汁系统中,含有EPA (16:0 - 20:5 PC)、亚油酸(16:0 - 18:2 PC)或花生四烯酸(16:0 - 20:4 PC)的磷脂酰胆碱(PC)的增加都降低了囊泡CH饱和度,并同样对CH结晶发挥了有效的剂量依赖性抑制作用。这些作用明显强于胆汁酸。最后,在胆囊上皮培养系统中,EPA显著抑制花生四烯酸诱导的粘液糖蛋白分泌。EPA对两种关键致病因子(CH结晶和粘液糖蛋白分泌)的双重抑制作用提示n-3 PUFA在CH胆石病的形成和预防中起关键作用。
项目成果
期刊论文数量(9)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Abei, M: "Clinical significance of trimethadione tolerance test. A useseful indicator of hepatic drug metabolizing capacity." Journal of Gastroenterology. 30. 478-484 (1995)
Abei,M:“三甲二酮耐受试验的临床意义。肝脏药物代谢能力的有用指标。”
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Abei M: "Clinical significance of trimethadione tolerance test. A useseful indicator of hepatic drug metaboilzing capacity." Journal of Gastroenterology. 30. 478-484 (1995)
阿贝 M:“三甲二酮耐受试验的临床意义。肝脏药物代谢能力的有用指标。”
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Abei M: "Clinical significance of trimethadione tolerance test.A useseful indicator of hepatic drug metabolizing capacity." Journal of Gastroenterology. 30. 478-484 (1995)
阿贝 M:“三甲二酮耐受试验的临床意义。肝脏药物代谢能力的一个有用指标。”
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Abei M: "Potency of phosphatidylcholine (PC) that contains fish oil (16 : 0-20 : 5 PC) in stabilizing biliary vesicles and inhibiting cholesterol crystallization : Comparison with other commo biliary PC or bile acid species in model bile" Gastroenterology
Abei M:“含有鱼油 (16 : 0-20 : 5 PC) 的磷脂酰胆碱 (PC) 稳定胆囊和抑制胆固醇结晶的功效:与模型胆汁中其他常见胆汁 PC 或胆汁酸种类的比较”胃肠病学
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Tomida S: "Long term effects of ursodeoxycholic acid in patients with cholecystolithiasis in comparis with the natural course of disease.A Cox proportional hazard model analysis." Gastroenterology. 112. A524 (1997)
Tomida S:“与自然病程相比,熊去氧胆酸对胆囊结石患者的长期影响。Cox 比例风险模型分析。”
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ABEI Masato其他文献
ABEI Masato的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ABEI Masato', 18)}}的其他基金
Evaluation of efficacy and safety of gene-chemotherapy for biliary cancers using oncolytic adenovirus armed with UPRT
UPRT 溶瘤腺病毒基因化疗治疗胆管癌的疗效和安全性评价
- 批准号:
22590755 - 财政年份:2010
- 资助金额:
$ 1.41万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Experimental Efficacy of Fiber-modified Cancer-selectively Replicating Adenovirus for Gene Therapy of Biliary Cancers
纤维修饰癌症选择性复制腺病毒用于胆道癌基因治疗的实验效果
- 批准号:
16390203 - 财政年份:2004
- 资助金额:
$ 1.41万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Experimental Efficacy of Adenovirus-mediated Gene Therapy for Gallbladder Cancer
腺病毒介导的胆囊癌基因治疗的实验疗效
- 批准号:
13670489 - 财政年份:2001
- 资助金额:
$ 1.41万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Animal study and clinical efficacy of fish oil (eicosapentaenoic acid) on dissolution of cholesterol gallstones.
鱼油(二十碳五烯酸)溶解胆胆固醇结石的动物研究和临床疗效。
- 批准号:
10670448 - 财政年份:1998
- 资助金额:
$ 1.41万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
相似海外基金
Modulation of the biliary immune niche by the microbiome
微生物组对胆道免疫生态位的调节
- 批准号:
10349405 - 财政年份:2023
- 资助金额:
$ 1.41万 - 项目类别:
The Natural History of Overall Mortality with Diagnosed Symptomatic Gallstone Disease in the United States: A Sequential Mixed-methods Study Evaluating Emergency, Non-emergency, and No Cholecystectomy
美国诊断有症状胆结石病的总体死亡率的自然史:一项评估紧急、非紧急和不进行胆囊切除术的序贯混合方法研究
- 批准号:
10664339 - 财政年份:2023
- 资助金额:
$ 1.41万 - 项目类别:
Koli: A non-surgical solution for gallstone disease
Koli:胆结石疾病的非手术解决方案
- 批准号:
10698949 - 财政年份:2023
- 资助金额:
$ 1.41万 - 项目类别:
SBIR Phase II: High Surface Area (HSA) Intraluminal Cryoablation for the Treatment of High-Risk Patients with Gallstone Disease
SBIR II 期:高表面积 (HSA) 腔内冷冻消融治疗高危胆石病患者
- 批准号:
2214634 - 财政年份:2022
- 资助金额:
$ 1.41万 - 项目类别:
Cooperative Agreement
Searching the blood metabolome to identify risk biomarkers for biliary tract cancer
搜索血液代谢组以确定胆道癌的风险生物标志物
- 批准号:
10614032 - 财政年份:2022
- 资助金额:
$ 1.41万 - 项目类别:
Searching the blood metabolome to identify risk biomarkers for biliary tract cancer
搜索血液代谢组以确定胆道癌的风险生物标志物
- 批准号:
10453004 - 财政年份:2022
- 资助金额:
$ 1.41万 - 项目类别:
Mechanisms of gallbladder smooth muscle dysfunction
胆囊平滑肌功能障碍的机制
- 批准号:
10667646 - 财政年份:2022
- 资助金额:
$ 1.41万 - 项目类别:
Metabolomics of symptomatic gallstone disease in COMETS
COMETS 中症状性胆石病的代谢组学
- 批准号:
10358593 - 财政年份:2021
- 资助金额:
$ 1.41万 - 项目类别:
SBIR Phase I: High Surface Area (HSA) Intraluminal Cryoablation for the Treatment of High-risk Patients with Gallstone Disease
SBIR 第一期:高表面积 (HSA) 腔内冷冻消融治疗胆石病高危患者
- 批准号:
1938608 - 财政年份:2020
- 资助金额:
$ 1.41万 - 项目类别:
Standard Grant